financetom
Business
financetom
/
Business
/
Avocado seller Mission Produce Q3 revenue beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Avocado seller Mission Produce Q3 revenue beats estimates
Sep 8, 2025 1:26 PM

Overview

* Mission Produce ( AVO ) fiscal Q3 revenue rises 10%, beating analyst expectations, per LSEG data

* Adjusted EPS for fiscal Q3 beats consensus, per LSEG data

* Adjusted EBITDA increased 3%, driven by higher avocado production

Outlook

* Company expects Q4 avocado volumes to rise 15% year-over-year

* Mission forecasts Q4 avocado pricing to drop 20-25% from last year

* Company projects 105-110 mln pounds of Peruvian avocado exports in Q4

* Mission anticipates increased blueberry volumes, offset by lower prices

Result Drivers

* PERUVIAN PRODUCTION - Higher Peruvian avocado production due to favorable weather increased supply and sales

* INTERNATIONAL FARMING - Significant growth in avocado production from owned orchards boosted revenue

* MARKETING & DISTRIBUTION - Increased avocado volume sold, despite a decrease in average sales prices, drove revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $357.70 $320.20

Revenue mln mln (2

Analysts

)

Q3 Beat $0.26 $0.14 (2

Adjusted Analysts

EPS )

Q3 EPS $0.21

Q3 Beat $18.20 $11.10

Adjusted mln mln (1

Net Analyst)

Income

Q3 Net $14.50

Income mln

Q3 Beat $32.60 $25 mln

Adjusted mln (2

EBITDA Analysts

)

Q3 Gross $45.10

Profit mln

Q3 $19.80

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the fishing & farming peer group is "buy"

* Wall Street's median 12-month price target for Mission Produce Inc ( AVO ) is $17.00, about 25.7% above its September 5 closing price of $12.63

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neuronetics Q3 revenue misses estimates
Neuronetics Q3 revenue misses estimates
Nov 4, 2025
Overview * Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations * U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis * CEO Keith J. Sullivan to retire in June 2026, search for successor underway Outlook * Company expects Q4 2025 revenue between $40 mln and $43 mln * Neuronetics ( STIM ) revises 2025...
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
Nov 4, 2025
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc ( RPRX ) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s...
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
Nov 4, 2025
Overview * InspireMD ( NSPR ) Q3 revenue grows 39% yr/yr, beating analyst expectations * Net income for Q3 beats analyst estimates despite larger net loss * Company attributes revenue growth to U.S. launch and international market penetration Outlook * InspireMD ( NSPR ) highlights strong demand for its CGuard Prime globally * Company emphasizes strategic focus on U.S. commercial...
Sotera Health beats Q3 estimates, raises FY profit guidance
Sotera Health beats Q3 estimates, raises FY profit guidance
Nov 4, 2025
Overview * Sotera Health ( SHC ) Q3 revenue rose 9.1% to $311 mln, beating analyst expectations * Adjusted EPS for Q3 increased to $0.26, surpassing analyst estimates * Adjusted EBITDA for Q3 rose 12.2% to $164 mln, exceeding expectations Outlook * Sotera Health ( SHC ) raises 2025 Adjusted EBITDA growth range to 6.75%-7.75% * Company reaffirms 2025 net...
Copyright 2023-2026 - www.financetom.com All Rights Reserved